ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2616

The Effect of Smoking on Response to Tumor Necrosis Factor-Alpha Inhibitor Treatment in Ankylosing Spondylitis Patients: Results from the Turkbio Registry

Handan Yarkan1, Gerçek Can1, Sedat Capar2, Berrin Zengin1, Gokce Kenar1, Servet Akar3, Ediz Dalkiliç4, Soner Senel5, Suleyman Serdar Koca6, Abdurrahman Tufan7, Ayten Yazici8, Nevsun İnanç9, Hülya Ellidokuz10, Nurullah Akkoc11 and Fatos Onen1, 1Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, 2Statistics, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, 3Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, Izmir, Turkey, 4Department of Internal Medicine, Division of Rheumatology, Uludağ University Faculty of Medicine, Bursa, Turkey, 5Rheumatology, Kayseri Erciyes University, Faculty of Medicine, Kayseri, Turkey, 6Rheumatology, Firat University Faculty of Medicine, Elazığ, Turkey, 7Internal Medicine-Rheumatology, Gazi University Faculty of Medicine, Ankara, Turkey, 8Rheumatology, Kocaeli University, Faculty of Medicine, Kocaeli, Turkey, 9Rheumatology, Marmara University faculty of Medicine, İstanbul, Turkey, 10Statistics, Dokuz Eylül Üniversity Faculty of Medicine, IZMIR, Turkey, 11Rheumatology, İzmir, Turkey, İzmir, Turkey

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS) and tumor necrosis factor (TNF)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Although there is good evidence that smoking has a dose-dependent impact on structural damage progression in ankylosing spondylitis (AS) the evidence is poor for its impact on disease activity, physical mobility, life quality and treatment response.

Therefor we aimed to investigate the impact of smoking on disease activity, treatment adherence and treatment response in Turkish patients with AS treated with their first tumour necrosis factor-alpha inhibitor (TNFi) therapy in a real-life cohort.

Methods: 561 patients fulfilling the modified New York criteria for AS and treated with their first TNFi therapy (including adalimumab, certolizumab, etanercept, golimumab and infliximab) since 2009 from 9 centers in Turkey were included in the analysis.

Treatment response was evaluated as achievement of ÒBASDAI50Ó or ÒASDAS Clinically important improvement (CII)Ó at the 3-monthsÕ and 6 monthsÕ visits. We classified patients as ÔrespondersÕ if they achieved clinical response at the both 3-monthsÕ and 6 monthsÕ visits.

Clinical and demographic parameters were compared between current/never and current/previous smoker groups. Demographic and descriptive data are presented by medians/interquartile ranges (IQRs). Groups were compared by non- parametric tests (x2, Kruskal Wallis and Mann Whitney tests).

Results: Among 561 AS patients analysed (40 % women, mean age:37.9 ± 11), 506 (90 %) had known smoking status. The median follow-up time was 1.9 years (IQR 0.85-3.5) and disease duration was 3.1 years (0,6-7,7).

At baseline, current smokers were younger compared with never and previous smokers. Current smokers had male predominance; lower erythrocyte sedimentation rate and higher change in BASMI at 3 months compared with never smokers. HLA status, body mass index, CRP, baseline disease indexes (BASDAI, BASFI, BASMI, ASDAS) and treatment response was not found to be different between current and never smoker patients in our population.  (Table 1).

Treatment adherence was better in previous smokers compared with current smokers but no difference was found between current and never smoker patients (Table 1).

In multivariate analysis, male (OR:1,98; 95% CI (1,39-2,82), p<0,01), HLA positive (OR:1,54; 95%CI (1,08-2,18), p=0,016) and active DMARD user (OR:1,84; (95%CI 1,12-3,01) p=0,015) patients had better treatment response and treatment adherence ((HR:1,93; 95% CI (1,36- 2,73); HR:1,60; 95% CI (1,13-2,27); HR:1,80; 95% CI (1,10-2,95) all p<0,005) but smoking status were not significant (p>0,05).

Conclusion:

This study suggested that smoking might not be associated with disease activity, treatment adherence and treatment response in AS patients treated with TNFi in clinical practice.

Table 1. Baseline demographic and clinical features; and treatment adherence and responses in study groups

Smoking status

Current

Never

Previus

P*

Current

never

P**

Current

previus

Smoking status unknown

Number, n (%)_

209 (37)

199 (35,5)

98 (17,5)

55 (10)

Age, median (IQR), years

34 (29-41)

38 (30-46)

42 (34-49)

0,007

<0,001

38 (29-48)

Women, n (%)

61 (27.2)

114 (50.9)

22 (9.8)

<0.001

0.37

27 (12.1)

HLA positivity, n (%)

84 (37,0)

77 (33,9)

54 (23,8)

0,23

0,4

12 (5,3)

Disease duration, median (IQR), years

3,5 (0,7-9,2)

3,5 (1-7,1)

3,5 (0,6-8,7)

0,1

0,5

0,1 (0-4,6)

Follow up time , median (IQR), years

2,3 (0,8-3,5)

1,7 (0,8-2,9)

3,4 (1,6-5,1)

0,13

<0,001

0,9 (0,4-1,6)

Treatment response n, (%)

133 (39,9)

120 (36)

59 (17,7)

0,53

0,37

21 (6,3)

DMARD use, n(%)

12 (21,1)

22 (38,6)

13 (22,8)

0,05

0,08

10 (17,5)

CRP, mg/L, median (IQR)

11 (4-25)

14 (5-29)

13 (6-30)

0,37

0,25

9 (5-19)

ESR, mm/h, median (IQR)

28 (13-42)

34 (20-49)

24,5 (12-44.2)

0,003

0,63

30 (14-43)

BASDAI,  median (IQR)

45 (34-60)

46 (36-57)

52 (37-62)

0,9

0,1

60 (44-71)

BASFI,  median (IQR)

25,5 (17-43)

25,5 (16-38)

25 (13-39,5)

0,5

0,5

48,5 (23,7-63)

BASMI,  median (IQR)

30 (9,5-50)

15 (4-30)

25 (6,2-50)

0,11

0,8

30 (20-57,5)

ASDAS

3,4 (2,6-4)

3,3 (2,2-3,9)

3,4 (2,7-3,9)

0,3

0,99

3,5 (2,4-4,1)

Stop reason n(%)

            Advers events

7 (30,4)

7 (30,4)

4 (17,4)

0.3

0.3

5 (21,7)

       Lack of efficacy

17 (24,2)

24 (34,2)

16 (22,8)

14 (20)

            Other

33 (41,3)

25 (31,3)

15 (18,8)

7 (8,8)

Changes at 3 months_

BASDAI,  median (IQR)

37 (25-50)

37 (24-50)

40 (26.7-53)

0.82

0.68

45 (27.5-62)

BASFI, median (IQR)

22 (12.5-35)

19 (13-32)

19.5 (11-30)

0.44

0.2

29 (15-51)

BASMI, median (IQR)

40 (10-57.5)

10 (4-30)

30 (10-50)

0.04

0.58

30 (20-60)

ASDAS, median (IQR)

2.2 (1.4-3.1)

2.2 (1.2-3.3)

2,4 (1.7-3.3)

0.97

0.24

2.4 (1.3-3.5)


Disclosure: H. Yarkan, None; G. Can, None; S. Capar, None; B. Zengin, None; G. Kenar, None; S. Akar, None; E. Dalkiliç, None; S. Senel, None; S. S. Koca, None; A. Tufan, None; A. Yazici, None; N. İnanç, None; H. Ellidokuz, None; N. Akkoc, None; F. Onen, None.

To cite this abstract in AMA style:

Yarkan H, Can G, Capar S, Zengin B, Kenar G, Akar S, Dalkiliç E, Senel S, Koca SS, Tufan A, Yazici A, İnanç N, Ellidokuz H, Akkoc N, Onen F. The Effect of Smoking on Response to Tumor Necrosis Factor-Alpha Inhibitor Treatment in Ankylosing Spondylitis Patients: Results from the Turkbio Registry [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/the-effect-of-smoking-on-response-to-tumor-necrosis-factor-alpha-inhibitor-treatment-in-ankylosing-spondylitis-patients-results-from-the-turkbio-registry/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-effect-of-smoking-on-response-to-tumor-necrosis-factor-alpha-inhibitor-treatment-in-ankylosing-spondylitis-patients-results-from-the-turkbio-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology